JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Sanchez, Gina; Reinhardt, Adam; Ramsey, Suzanne; Wittkowski, Helmut; Hashkes, Philip; Berkun, Yackov; Schalm, Susanne; Murias, Sara; Dare, Jason; Brown, Diane; Stone, Deborah; Gao, Ling; Klausmeier, Thomas; Foell, Dirk; De Jesus, Adriana; Chapelle, Dawn; Kim, Hanna; Dill, Samantha; Colbert, Robert; Failla, Laura; Kost, Bahar; O'Brien, Michelle; Reynolds, James; Folio, Les; Calvo, Katherine; Paul, Scott; Weir, Nargues; Brofferio, Alessandra; Soldatos, Ariane; Biancotto, Angelique; Cowen, Edward; Digiovanna, John; Gadina, Massimo; Lipton, Andrew; Hadigan, Colleen; Holland, Steven; Fontana, Joseph; Alawad, Ahmad; Brown, Rebecca; Rother, Kristina; Heller, Theo; Brooks, Kristina; Kumar, Parag; Brooks, Stephen; Waldman, Meryl; Singh, Harsharan; Nickeleit, Volker; Silk, Maria; Prakash, Apurva; Janes, Jonathan; ÖZEN, SEZA; Wakim, Paul; Brogan, Paul; Macias, William; Goldbach-Mansky, Raphaela

doi:10.1172/jci98814

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Sanchez G. A. M., Reinhardt A., Ramsey S., Wittkowski H., Hashkes P. J., Berkun Y., ...More

JOURNAL OF CLINICAL INVESTIGATION, vol.128, no.7, pp.3041-3052, 2018 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 128 Issue: 7
Publication Date: 2018
Doi Number: 10.1172/jci98814
Journal Name: JOURNAL OF CLINICAL INVESTIGATION
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.3041-3052
Hacettepe University Affiliated: Yes

Abstract

BACKGROUND. Monogenic IFN-mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality. We used the JAK inhibitor baricitinib, with IFN-blocking activity in vitro, to ameliorate disease.